Chemistry: molecular biology and microbiology – Micro-organism – tissue cell culture or enzyme using process... – Recombinant dna technique included in method of making a...
Reexamination Certificate
2006-07-18
2006-07-18
Chernyshev, Olga N. (Department: 1649)
Chemistry: molecular biology and microbiology
Micro-organism, tissue cell culture or enzyme using process...
Recombinant dna technique included in method of making a...
C435S069100, C435S320100, C435S252300, C435S252330, C435S252800, C435S254100, C435S254200, C435S255100, C435S255500, C424S093200, C424S093210, C424S093400, C424S093500, C424S093510, C424S192100, C424S193100, C424S194100
Reexamination Certificate
active
07078191
ABSTRACT:
The present invention relates to novel compositions useful for elucidating the onset or progress of diseases such as Huntington's disease, that are associated with the formation of fibrils or protein aggregates. Further, the present invention relates to methods for monitoring formation of fibrils or protein aggregates as well as to methods for identifying inhibitors of fibril or protein aggregate formation. Additionally, the invention relates to inhibitors of the formation of fibrils or protein aggregates identified by the method of the invention as well as to pharmaceutical compositions that include the inhibitors.
REFERENCES:
patent: 5234814 (1993-08-01), Card et al.
patent: 5593846 (1997-01-01), Schenk et al.
patent: 5723301 (1998-03-01), Burke et al.
patent: 5795963 (1998-08-01), Mullan
patent: 0 206302 (1986-12-01), None
patent: 0 293 249 (1988-11-01), None
patent: 0 854 364 (1998-07-01), None
patent: WO95/29243 (1995-11-01), None
patent: WO96/12544 (1996-05-01), None
patent: WO96/28471 (1996-09-01), None
patent: WO97/17445 (1997-05-01), None
Onodera et al., FEBS Letters, 1996, 399, pp. 135-139.
Evin et al., 1994, Int. J. Exp. Clin Invest., 1, p. 263-280.
Kisilevsky et al., “Arresting amyloidosisin vivousing small-module anionic sulphonates or sulphates: Implications for Alzheimer's disease”, (Feb. 1995), pp. 143-148,Nature Medicine, vol. 1, No. 2.
Trottler et al., “Polyglutamine expansion as a pathological epitope in Huntington's disease and four dominant Cerebellar ataxias”, (Nov. 23, 1985), pp. 403-406,Naturevol. 378.
Gutekunst et al., “Identification and localization of huntingtin in brain and human lymphoblastoid cell lines with anti-fusion protein antibodies”, (Sep. 1995), pp. 8710-8714,Pro. Natl. Acad. Sci. USAvol. 92 Neurobiology.
M.F. Perutz, “Glutamine repeats and inherited neurodegenerative diseases: molecular aspects”, (1996) pp. 848-858,MRC Laboratory of Molecular Biology.
Mangiarini et al., “Exon 1 of the HD gene with an expanded CAG repeat is sufficient to cause a progressive neurological phenotype in transgenic mice”, (Nov. 1, 1996), pp. 493-506,Cell, vol. 87.
Stott et al., “Incorporation of glutamine repeats makes protein oligomerize: implications for neurodegenerative Diseases”, (Jul. 1995), pp. 6509-6513,Pro. Natl. Acad. Sci. USA, vol. 92, Biochemistry.
Merlini et al., “Interaction of the anthracycline 4′-iodo-4′-deoxydoxorubicin with amyloid fibrils: Inhibition of amyloidogenesis”, (Mar. 1995), pp. 2959-2963,Proc. Natl. Acad. Sci. USA, vol. 92, Medical Sciences.
Scherzinger, et al., “Huntingtin-encoded polyglutamine expansions form amyloid-like protein aggregatesin vitroandin vivo”, (Aug. 8, 1997), pp. 549-558,Cell, vol. 90.
Davies et al., “Formation of neuronal intranuclear inclusions underlies the neurological dysfunction in mice Transgenic for the HD mutation”, (Aug. 8, 1997), pp. 537-548,Cell, vol. 90.
Derwent, “Nucleic acid fragments associated with spinocerebellar ataxis type 2-contain increased number of CAG repeat region compared to normal gene”, (May 7, 1998), XP-002101183.
Tateishe et al., “Removal of causative agent of creutzefeldt-jakob disease (CJD) through membrane filtration method”, (1993), pp. 357-362,Membrane, 18(6).
The Huntington's Disease Collaborative Research Group, “A Novel Gene Containing a Trinucleotide Repeat That is Expanded and Unstable on Huntington's Disease Chromosomes”, Cell, Mar. 26, 1993, vol. 72, 971-983.
Bates, G.P. et al., Transgenic models of Huntington's disease. Hum Mol Genet. 1997;6(10):1633-7.
Becher, M.W. et al., Intranuclear neuronal inclusions in Huntington's disease and dentatorubral and pallidoluysian atrophy: correlation between the density of inclusions and ITI5 CAG triplet repeat length. Neurobiol Dis. Apr. 1998;4(6):387-97.
Beyreuther, K. et al., Alzheimer's disease. Tangle disentanglement. Nature. Oct. 10, 1996;383(6600):476-7.
Booth, D.R. et al., Instability, unfolding and aggregation of human lysozyme variants underlying amyloid fibrillogenesis. Nature. Feb. 27, 1997:385(6619):787-93.
Burke, J.R. et al., Huntingtin and DRPLA proteins selectively interact with the enzyme GAPDH. Nat Med. Mar. 1996;2(3):347-50.
Caputo, C.B. et al., Amyloid-like properties of a synthetic peptide corresponding to the carboxy terminus of beta-amyloid protein precursor. Arch Biochem Biophys. Jan. 1992;292(1):199-205.
Caughey, B. and Chesebro, B. Prion protein and the transmissible spongiform encephalopaties. Trends Cell Biol. 1997; 7: 56-62.
De Rooij, K.E. et al., Subcellular localization of the Huntington's disease gene product in cell lines by immunofluorescence and biochemical subcellular fractionation. Hum Mol Genet. Aug. 1996;5(8):1093-9.
Difiglia, M. et al., Aggregation of huntingtin in neuronal intranuclear inclusions and dystrophic neurites in brain. Science. Sep. 26, 1997;277(5334):1990-3.
Difiglia, M. et al., Huntingtin is a cytoplasmic protein associated with vesicles in human and rat brain neurons. Neuron. May 1995;14(5):1075-81.
Duyao, M.P. et al., Inactivation of the mouse Huntington's disease gene homolog Hdh. Science. Jul. 21, 1995;269(5222):407-10.
Georgalis, Y. et al., Huntingtin aggregation monitored by dynamic light scattering. Proc Natl Acad Sci U S A. May 26, 1998;95(11):6118-21.
Glenner, G.G. Amyloid deposits and amyloidosis. The beta-fibrilloses (first of two parts). N Engl J Med. Jun. 5, 1980;302(23):1283-92 and 1333-1343.
Goldberg, Y.P. et al., Cleavage of huntingtin by apopain, a proapoptotic cysteine protease, is modulated by the polyglutamine tract. Nat Genet. Aug. 1996;13(4):442-9.
HDCRG. A novel gene containing a trinucleotide repeat that is expanded and unstable on Huntington's disease chromosomes. The Huntington'Disease Collaborative Research Group. Cell. Mar. 26, 1993;72(6):971-83.
Holmberg, M. et al., Spinocerebellar ataxia type 7 (SCA7): a neurodegenerative disorder with neuronal intranuclear inclusions. Hum Mol Genet. May 1998;7(5):913-8.
Hoogeveen, A.T. et al., Characterization and localization of the Huntington disease gene product. Hum Mol Genet. Dec. 1993;2(12):2069-73.
Igarashi, S. et al., Suppression of aggregate formation and apoptosis by transglutaminase inhibitors in cells expressing truncated DRPLA protein with an expanded polyglutamine stretch. Nat Genet. Feb. 1998;18(20:111-7.
Ikeda, H. et al., Expanded polyglutamine in the Machado-Joseph disease protein induces cell death in vitro and in vivo. Nat Genet. Jun. 1996:13(2):196-202.
Jarrett, J.T. and Lansbury, P.T. Seeding “one-dimensional crystallization” of amyloid: a pathogenic mechanism in Alzheimer's disease and scrapie? Cell. Jun. 18, 1993;73(6):1055-8.
Kalchman, M.A. et al., HIP1, a human homologue of S. cerevisiae Sla2p, interacts with membrane-associated huntingtin in the brain. Nat Genet. May 1997;16(1):44-53.
Kalchman, M.A. et al., Huntingtin is ubiquitinated and interacts with a specific ubiquitin-conjugating enzyme. J Biol Chem. Aug. 9, 1996;271(32):19385-94.
Li, X.-J. et al., A huntingtin-associated protein enriched in brain with implications for pathology. Nature. Nov. 23, 1995;378(6555):398-402.
Lim, K. et al., Three-dimensional structure of Schistosoma japonicum glutathione S-transferase fused with a six-amino acid conserved neutralizing epitope of gp41 from HIV. Protein Sci. Dec. 1994;3(12):2233-44.
Matilla, A. et al., The cerebellar leucine-rich acidic nuclear protein interacts with ataxin-1. Nature. Oct. 30, 1997.389(6654):974-8. Erratum in: Nature Feb. 19, 1998;391(6669):818.
Onodera, O. et al., Toxicity of expanded polyglutamine-domain proteins inEscherichia coli. FEBS Lett. Dec. 9, 1996;399(1-2):135-9.
Paulson, H.L. et al., Intranuclear inclusions of expanded polyglutamine protein in spinocerebellar ataxia type 3. Neuron. Aug. 1997;19(2):333-44.
Perutz, M.F. et al., Glutamine repeats as polar zippers: their possible role in inherited neurodegenerative diseases. Proc Natl Acad Sci U S A. Jun. 7, 1994;91(12):5355
Bates Gillian
Lehrach Hans
Scherzinger Eberhard
Wanker Erich
Chernyshev Olga N.
Max-Planck-Gesellschaft zur Förderung Der Wissenschaften E.
LandOfFree
Composition and method for the detection of diseases... does not yet have a rating. At this time, there are no reviews or comments for this patent.
If you have personal experience with Composition and method for the detection of diseases..., we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Composition and method for the detection of diseases... will most certainly appreciate the feedback.
Profile ID: LFUS-PAI-O-3567632